... the drug and later developed diabetes. Reinstein has done studies, funded by AstraZeneca and two other drugmakers, that found that various medications, including Seroquel, carry an unexpected ... deposition for the Orlando case, Reinstein said he was unaware of any criticism from AstraZeneca about his research. But he had some criticisms of his own, according to an internal company e-mail filed in ...

... of the FTSE 100 Index, much smaller than its own offspring AstraZeneca. The Company is listed on the London Stock Exchange and is a ... late-stage clinical trials, on 19 June 2007 AstraZeneca completed the acquisition of vaccine maker MedImmune, paying $ ... 39;. Amid allegations of broken promises over this consolidation[26], AstraZeneca presented the new MedImmune to investors on 7 December 2007[27 ...

... approved for use of bipolar mania, and in 2006 it was approved for bipolar disorder. Yet AstraZeneca is now the defendant in thousands of lawsuits claiming, among other allegations, that the company actively ... to market it as a treatment for dementia in the elderly. In some of the retrieved documents, AstraZeneca employees and employees of a consulting firm hired by the company reference plans ...

... cutting its US sales force The Associated Press British drugmaker astrazeneca PLC plans to cut its US sales force by offering buyouts ... all 72 news articles » Read more: Drugmaker astrazeneca cutting its US sales force - The Associated Press Technorati Tags: and-anti-psychotic, associated, builders, Crestor, cutting-its, drugmaker-astrazeneca, img-alt, macintosh, months, plc, street, ...

... Duff Wilson in the New York Times, The pharmaceutical company AstraZeneca said Thursday that it had reached a $520 million agreement to ... both declined to comment. Here we go again. As the Times article noted, AstraZeneca, based in Britain, joins a list of drug ... negative consequences. We previously discussed allegations that AstraZeneca manipulated and suppressed clinical research, and organized ...

... diabetes drug was able to meet both the primary and secondary endpoints and shares of AstraZeneca and Bristol-Myers Squibb went up after few hours. However, the new data does not show any improvement ... the late stage trial. The mixed data report for dapagliflozin could be a cause of concern for both AstraZeneca and Bristol-Myers Squibb as analysts have high expectations from dapagliflozin and many ...